NovoCure (NASDAQ:NVCR – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect NovoCure to post earnings of ($0.34) per share and revenue of $161.30 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
NovoCure Price Performance
Shares of NVCR stock opened at $21.81 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44. The firm’s 50-day moving average is $27.23 and its two-hundred day moving average is $21.35. NovoCure has a 12 month low of $11.70 and a 12 month high of $34.13. The company has a market capitalization of $2.36 billion, a PE ratio of -15.58 and a beta of 0.62.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on NVCR. HC Wainwright reiterated a “buy” rating and set a $38.00 price target on shares of NovoCure in a research report on Tuesday, January 14th. Wedbush restated a “neutral” rating and issued a $29.00 price objective on shares of NovoCure in a report on Monday, January 13th. Evercore ISI upgraded shares of NovoCure from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $18.00 to $30.00 in a report on Monday, December 2nd. Finally, Piper Sandler lifted their price objective on shares of NovoCure from $28.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.67.
NovoCure Company Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.
Read More
- Five stocks we like better than NovoCure
- What does consumer price index measure?
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- What is the Hang Seng index?
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- What Are Treasury Bonds?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.
